Baker McKenzie advised the investment fund Asabys in an oversubscribed Series C funding round for SafeHeal, totaling EUR 10 million. This fundraising will enable SafeHeal to accelerate the commercialization of Colovac®, an innovative medical device for patients with colorectal cancer.
The extension round was led by Asabys Partners through its Sabadell Asabys II fund, joining a world-leading syndicate that includes Sofinnova Partners, Solar Eclipse, Gideon Strategic Partners, Polis and M&L Healthcare.
The Baker McKenzie team was composed of the following:
• Corporate: Antoine Caillard (Senior Counsel, Paris); David Courchia (Senior Associate, Paris); Carlos Martin (Partner, Madrid); Emily Nash (Associate, Chicago)
• Employment Law: Jérémie Paubel (Partner, Paris); Roland Sèbe (Associate, Paris)